GLP-1 Receptor Agonists and the Thyroid: C-Cell Effects in Mice Are Mediated via the GLP-1 Receptor and not Associated with RET Activation
Open accessThe DOI matches its Crossref record; 27 of the 29 references it cites were found in a registry or an index.
Abstract
Liraglutide and exenatide are glucagon-like peptide receptor (GLP-1R) agonists used in the treatment of type 2 diabetes. Both molecules have been associated with the development of thyroid C-cell tumors after lifetime exposure in rodents. Previously, it has been reported that these tumors are preceded by increased plasma calcitonin and C-cell hyperplasia. We can now document that the murine C-cell effects are mediated via GLP-1R. Thus, 13 wk of continuous exposure to GLP-1R agonists was associated with marked increases in plasma calcitonin and in the incidence of C-cell hyperplasia in wild-type mice. In contrast, similar effects were not seen in GLP-1R knockout mice. Human C-cell cancer is often caused by activating mutations in the rearranged-during-transfection (RET) protooncogene. We developed an immunohistochemical method to assess RET activation in tissues. Liraglutide dosing to mice was not found to activate RET. Further evaluation of the signaling pathways demonstrated that liraglutide increased ribosomal S6, but not MAPK kinase, phosphorylation. These observations are consistent with effects of GLP-1R agonists on rodent C cells being mediated via mammalian target of rapamycin activation in a RET- and MAPK-independent manner.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Pharmacological studies in rodents support an association between the use of GLP-1 RAs and the development of medullary thyroid cancer (MTC) resulting in a black box warning for these agents in patients at risk for this condition.”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [45]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors
Daub, H., Ulrich Weiss, F., Wallasch, C., & Ullrich, A. (1996) · Nature · doi:10.1038/379557a0 · Cited by 1,476
Regulation of the mTOR Complex 1 Pathway by Nutrients, Growth Factors, and Stress
Sengupta, S., Peterson, T. R., & Sabatini, D. M. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.026 · Cited by 1,241
Bjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672 · cited 10×
“Two of these slides were stained by standard techniques with hematoxylin and eosin and immunohistochemistry (IHC) for calcitonin (7) and used for the histopathological diagnosis.”
BackgroundMethodResultInfluentialSelf-citationBuse, J. B., Nauck, M., Forst, T., Sheu, W. H.-H., Shenouda, S. K., Heilmann, C. R., Hoogwerf, B. J., Gao, A., Boardman, M. K., Fineman, M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61267-7 · Cited by 565
International Union of Pharmacology. XXXV. The Glucagon Receptor Family
Mayo, K. E., Miller, L. J., Bataille, D., Dalle, S., Göke, B., Thorens, B., & Drucker, D. J. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.1.6 · Cited by 506
GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting
Korner, M., Stockli, M., Waser, B., & Reubi, J. C. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.038679 · Cited by 477 · cited 1×
“In situ ligand binding We carried out ISLB on tissue sections as previously reported (7, 23).”
MethodThyroid Cancer Incidence Patterns in the United States by Histologic Type, 1992–2006
Aschebrook-Kilfoy, B., Ward, M. H., Sabra, M. M., & Devesa, S. S. (2011) · Thyroid · doi:10.1089/thy.2010.0021 · Cited by 454
Anatomy and embryology of the laboratory rat
Hebel, R., & Stromberg, M. W. (1986) · Cited by 440
Long-Acting Glucagon-Like Peptide 1 Receptor Agonists
Garber, A. J. (2011) · Diabetes Care · doi:10.2337/dc11-s231 · Cited by 350
Research works printed but not linked: 3
- DeLellis, 1994, Changes in structure and function of thyroid C-cell, 285
- Botts, 1991, Proliferative lesions of the thyroid and parathyroid glands, E-3, 1
- Boorman, 1996, C-cell hyperplasia, C-cell adenoma, and C-cell carcinoma, thyroid in rats, 262
Cited by
Pyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B. (2014) · Endocrinology · doi:10.1210/en.2013-1934 · Cited by 876
The Cardiovascular Biology of Glucagon-like Peptide-1
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665
Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560
Graaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
“GLP-1R agonists are capable of inducing increased calcitonin gene expression and C cell hyperplasia in the thyroid of wild-type, but not the GLP-1R knockout (Glp-1r2/2) mice (Yamada et al., 2008; Madsen et al., 2012).”
BackgroundWang, L., Xu, R., Kaelber, D. C., & Berger, N. A. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.21305 · Cited by 304
Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
McLean, B. A., Wong, C. K., Campbell, J. E., Hodson, D. J., Trapp, S., & Drucker, D. J. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnaa032 · Cited by 289
Seino, Y., & Yabe, D. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12065 · Cited by 247
Mabilleau, G., Mieczkowska, A., & Chappard, D. (2014) · Journal of Diabetes · doi:10.1111/1753-0407.12102 · Cited by 178
“In addition, in rodents the GLP-1 receptor is expressed on C-cells of the thyroid gland and GLP-1Ra have been shown to promote calcitonin secretion and are associated with the development of C-cell tumors in these animals.(24) However, such effects have not been observed in humans with up to 2 years treatment.”
BackgroundThe role of aging upon β cell turnover
Kushner, J. A. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64095 · Cited by 159
“For example, the glucagon-like peptide receptor signals, which are putative β cell regenerative signals, may also activate calcitonin-producing para-follicular cells (C cells) of the medullary thyroid (11).”
On-target and Off-target-based Toxicologic Effects
Rudmann, D. G. (2012) · Toxicologic Pathology · doi:10.1177/0192623312464311 · Cited by 176
“Rosol reviewed the published carcinogenicity data for GLP-1 agonists in rodents as well as the mechanism of action work done to date by Nova Nordisk (Knudsen et al. 2010; Madsen et al. 2012).”
MethodPereira, M., Jeyabalan, J., Jørgensen, C. S., Hopkinson, M., Al-Jazzar, A., Roux, J. P., Chavassieux, P., Orriss, I. R., Cleasby, M. E., & Chenu, C. (2015) · Bone · doi:10.1016/j.bone.2015.08.006 · Cited by 137
Exendin-4, a GLP-1 Receptor Agonist, Attenuates Prostate Cancer Growth
Nomiyama, T., Kawanami, T., Irie, S., Hamaguchi, Y., Terawaki, Y., Murase, K., Tsutsumi, Y., Nagaishi, R., Tanabe, M., Morinaga, H., et al. (2014) · Diabetes · doi:10.2337/db13-1169 · Cited by 136
“In a previous report (37), a 13-week continuous exposure to liraglutide, a GLP-1R agonist, was associated with a marked increase in plasma calcitonin levels and thyroid C-cell hyperplasia in wild-type mice, but not in GLP-1R– deficient mice.”
BackgroundHu, W., Song, R., Cheng, R., Liu, C., Guo, R., Tang, W., Zhang, J., Zhao, Q., Li, X., & Liu, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.927859 · Cited by 127
“First, it was reported that the mechanism of C-cell transformation in rodents is by activation of the GLP-1 receptor on the C cell, and a study has shown that GLP-1 receptor stimulation is a better predictor of C-cell hyperplasia than plasma drug concentrations of exenatide and liraglutide (66, 67).”
BackgroundSafety and tolerability of new-generation anti-obesity medications: a narrative review
Patel, D. K., & Stanford, F. C. (2018) · Postgraduate Medicine · doi:10.1080/00325481.2018.1435129 · Cited by 116
“GLP-1 receptor agonists can cause thyroid C-cell hyperplasia and calcitonin release in mice [78].”
BackgroundMabilleau, G., Mieczkowska, A., Irwin, N., Flatt, P. R., & Chappard, D. (2013) · Journal of Endocrinology · doi:10.1530/joe-13-0146 · Cited by 106
“5-fold increase in circulating plasma calcitonin (Madsen et al. 2012).”
Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency
Alavi, S. E., Cabot, P. J., & Moyle, P. M. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00308 · Cited by 95
Iwaya, C., Nomiyama, T., Komatsu, S., Kawanami, T., Tsutsumi, Y., Hamaguchi, Y., Horikawa, T., Yoshinaga, Y., Yamashita, S., Tanaka, T., et al. (2017) · Endocrinology · doi:10.1210/en.2017-00461 · Cited by 87
“marked increase in plasma calcitonin levels and thyroid C-cell hyperplasia in wild-type mice but not in GLP-1Rdeficient mice (23).”
BackgroundBaxter, S. M., Lund, L. C., Andersen, J. H., Brix, T. H., Hegedüs, L., Hsieh, M. H.-C., Su, C. T.-T., Cheng, M. C.-Y., Chang, Z. C.-J., Lai, E. C.-C., et al. (2025) · Thyroid® · doi:10.1089/thy.2024.0387 · Cited by 81
“9,10 However, the relevance to humans is undetermined.”
GLP1 and cancer: friend or foe?
Vangoitsenhoven, R., Mathieu, C., & Van der Schueren, B. (2012) · Endocrine-Related Cancer · doi:10.1530/erc-12-0111 · Cited by 73
“Recently, the group of Madsen et al. (2012) reported that liraglutide binding to the GLP1 receptor on C cells leading tot C-cell hyperplasia in wild type mice does not lead to RET kinase activation, but rather mTOR activation, which is reassuring to a certain extent as activation of this RET…”
Lim, S. K., Kim, K. M., & Nauck, M. A. (2018) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2018.01.011 · Cited by 76
Diabetes and Thyroid Cancer Risk: Literature Review
Shih, S.-R., Chiu, W.-Y., Chang, T.-C., & Tseng, C.-H. (2012) · Experimental Diabetes Research · doi:10.1155/2012/578285 · Cited by 67
“Glucagon-like pepide-1 receptor activation promotes C-cell proliferation and medullary thyroid cancer in rodents [54, 55].”
BackgroundHegedüs, L., Sherman, S. I., Tuttle, R. M., von Scholten, B. J., Rasmussen, S., Karsbøl, J. D., Daniels, G. H., & for the LEADER Publication Committee on behalf of the LEADER Trial Investigators (2018) · Diabetes Care · doi:10.2337/dc17-1956 · Cited by 67
GLP-1RA Use and Thyroid Cancer Risk
Brito, J. P., Herrin, J. S., SWARNA, K. S., Ospina, N. S., Montori, V. M., Toro-Tobón, D., Umpierrez, G. E., Galindo, R. J., Deng, Y., Mickelson, M. M., et al. (2025) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2024.4852 · Cited by 76
Potential side effects to GLP-1 agonists: understanding their safety and tolerability
Consoli, A., & Formoso, G. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.987122 · Cited by 63
“The molecular mechanism behind these effects apparently involves the mTOR pathway rather than rearranged during transfection proto-oncogene activation [62].”
BackgroundA Review on the Association between Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer
Chiu, W.-Y., Shih, S.-R., & Tseng, C.-H. (2012) · Experimental Diabetes Research · doi:10.1155/2012/924168 · Cited by 63
“[33] documented that C-cell hyperplasia and calcitonin release associated with GLP-1 agonists in wildtype mice were GLP-1-receptor dependent.”
BackgroundOn-target Effects of GLP-1 Receptor Agonists on Thyroid C-cells in Rats and Mice
Rosol, T. J. (2013) · Toxicologic Pathology · doi:10.1177/0192623312472402 · Cited by 61
“The mode of action for C-cell tumorigenesis in rats and mice by long-acting GLP-1R agonists indicates that diffuse C-cell hyperplasia should precede focal C-cell hyperplasia as described for the actions of liraglutide in mice (Madsen et al. 2012a).”
BackgroundInfluentialThe effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer
Ibrahim, S. S., Ibrahim, R. S., Arabi, B., Brockmueller, A., Shakibaei, M., & Büsselberg, D. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10192-9 · Cited by 56
Inventing Liraglutide, a Glucagon-Like Peptide-1 Analogue, for the Treatment of Diabetes and Obesity
Knudsen, L. B. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00048 · Cited by 56
Roy, S., Ghosh, A., Majie, A., Karmakar, V., Das, S., Dinda, S. C., Bose, A., & Gorain, B. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155638 · Cited by 64
Panganiban, J. A., Kehar, M., Ibrahim, S. H., Hartmann, P., Sood, S., Hassan, S. M., Ramirez, C. M., Kohli, R., Censani, M., Mauney, E. E., et al. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100164 · Cited by 73
An Updated Review on Cancer Risk Associated with Incretin Mimetics and Enhancers
Tseng, C.-H., Lee, K.-Y., & Tseng, F.-H. (2015) · Journal of Environmental Science and Health, Part C · doi:10.1080/10590501.2015.1003496 · Cited by 49
“By using CD-1 wild-type and GLP-1R knockout mice as models, Madsen and colleagues [129] documented that GLP-1R agonists (exenatide and liraglutide) induced calcitonin release and C-cell hyperplasia in rodents, which were GLP-1R dependent, mediated via mammalian target of rapamycin (mTOR), but independent of rearranged…”
BackgroundMethodInfluentialMieczkowska, A., Mansur, S., Bouvard, B., Flatt, P. R., Thorens, B., Irwin, N., Chappard, D., & Mabilleau, G. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2845-8 · Cited by 49
“Furthermore, we cannot rule out other extra-pancreatic consequences of double incretin receptor knock-out on calcitonin and glucocorticoid secretions and modifications of adipokine network as previously observed [6, 37-39].”
ResultGLP-1 agonists in type 1 diabetes
Pettus, J., Hirsch, I. B., & Edelman, S. V. (2013) · Clinical Immunology · doi:10.1016/j.clim.2013.04.006 · Cited by 48
“Continuous exposure to GLP-1 agonists resulted in C-cell hyperplasia and carcinoma in rats and mice with the same finding not resulting in GLP-1r knockout mice [49].”
BackgroundPatoulias, D., Doumas, M. N., Kotsis, V., Stavropoulos, K., Imprialos, K. P., Zografou, I., Petidis, K., Bakatselos, S., & Karagiannis, A. I. (2020) · Current Diabetes Reviews · doi:10.2174/1573399815666190614141918 · Cited by 53
Bethel, M. A., Patel, R. A., Thompson, V. P., Merrill, P., Reed, S. D., Li, Y., Ahmadi, S., Katona, B. G., Gustavson, S. M., Ohman, P., et al. (2019) · Diabetes Care · doi:10.2337/dc18-2028 · Cited by 43
“In contrast, preclinical studies with exenatide demonstrated increased incidence of C-cell adenomas (not carcinomas) in female rats at exposures 130 times the clinical dose and no C-cell pathology in mice (6).”
BackgroundResultDaniels, G. H., Hegedüs, L., Marso, S. P., Nauck, M. A., Zinman, B., Bergenstal, R. M., Mann, J. F. E., Derving Karsbøl, J., Moses, A. C., Buse, J. B., et al. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12444 · Cited by 42
“C-cell pathology was absent in liraglutide-treated GLP-1 receptor knockout animals [3,4],”
BackgroundIncretin-based therapies in the treatment of type 2 diabetes — More than meets the eye?
Łabuzek, K., Kozłowski, M., Szkudłapski, D., Sikorska, P., Kozłowska-Geller, M. A., & Okopień, B. (2013) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2013.01.009 · Cited by 47
Jung, M. J., & Kwon, S. K. (2014) · Endocrinology and Metabolism · doi:10.3803/enm.2014.29.4.536 · Cited by 38
Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?
Lisco, G., De Tullio, A., Disoteo, O., Piazzolla, G., Guastamacchia, E., Sabbà, C., De Geronimo, V., Papini, E., & Triggiani, V. (2023) · Endocrine Connections · doi:10.1530/ec-23-0257 · Cited by 37
“Evidence from rodent studies suggested that GLP-1RAs may stimulate parafollicular C-cells proliferation, potentially affecting the risk of new-onset medullary thyroid neoplasms.”
InfluentialManagement Strategies for Posttransplant Diabetes Mellitus after Heart Transplantation: A Review
Cehic, M. G., Nundlall, N., Greenfield, J. R., & Macdonald, P. S. (2018) · Journal of Transplantation · doi:10.1155/2018/1025893 · Cited by 42
Incretin-based therapies in prediabetes: Current evidence and future perspectives
Papaetis, G. S. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i6.817 · Cited by 37
Byrd, R. A., Sorden, S. D., Ryan, T., Pienkowski, T., LaRock, R., Quander, R., Wijsman, J. A., Smith, H. W., Blackbourne, J. L., Rosol, T. J., et al. (2015) · Endocrinology · doi:10.1210/en.2014-1722 · Cited by 36
“Although molecular mechanisms were not examined in these studies, work by Madsen et al (4) demonstrated that the C-cell effects in mice are mediated by the GLP-1 receptor and are not associated with activation of the rearranged-during-transfection protooncogene.”
Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists
Sandsdal, R. M., Juhl, C. R., & Torekov, S. S. (2019) · Drug Safety · doi:10.1007/s40264-019-00812-7 · Cited by 40
Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review
Espinosa De Ycaza, A. E., Brito, J. P., McCoy, R. G., Shao, H., & Singh Ospina, N. (2024) · Thyroid · doi:10.1089/thy.2023.0530 · Cited by 37
“23,44,45 The association between GLP-1 RAs and MTC in humans has not been proven, and studies have shown interspecies differences regarding the density of GLP-1 receptors and responses to GLP-1 RA activation in the thyroid, limiting the predictive value of nonhuman preclinical studies on humans.”
Ko, A., Chang, Y.-C., Bahar, F., Wang, T. H., Xanthavanij, N., Yu, C.-C., Hsieh, R. J.-L., See, X. Y., Lo, S., Song, J., et al. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-02237 · Cited by 57
Barrea, L., Pugliese, G., Muscogiuri, G., Laudisio, D., Colao, A. A. L., & Savastano, S. (2020) · Minerva Endocrinology · doi:10.23736/s0391-1977.20.03179-x · Cited by 38
Dambach, D. M., Misner, D., Brock, M., Fullerton, A. M., Proctor, W. R., Maher, J. M., Lee, D. H., Ford, K. A., & Diaz, D. (2015) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5b00396 · Cited by 37
Boland, C. L., DeGeeter, M., Nuzum, D. S., & Tzefos, M. (2013) · Annals of Pharmacotherapy · doi:10.1345/aph.1r444 · Cited by 33
Alliances of the gut and bone axis
Hansen, M. S., & Frost, M. (2021) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2021.06.024 · Cited by 34
Effect of GLP1R agonists taspoglutide and liraglutide on primary thyroid C-cells from rodent and man
Boess, F., Bertinetti-Lapatki, C., Zoffmann, S., George, C., Pfister, T., Roth, A., Lee, S. M. L., Thasler, W. E., Singer, T., & Suter, L. (2013) · Journal of Molecular Endocrinology · doi:10.1530/jme-12-0186 · Cited by 29
“Moreover, it has been shown that C-cell hypertrophy in mice is GLP1R dependent and is not observed in Glp1r knockout mice (Madsen et al. 2012).”
BackgroundResultApproach to the patient with thyroid nodules: considering GLP-1 receptor agonists
Kelly, C. A., & Sipos, J. A. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae722 · Cited by 30
Grigoriadis, G., Koufakis, T., & Kotsa, K. (2023) · Medicina · doi:10.3390/medicina59112013 · Cited by 37
“Regarding incretin mimetics, animal [105] and human observational [106] data suggest an increased risk of MTC after treatment with glucagon-like peptide-1 receptor agonists.”
BackgroundA molecular rheostat at the interface of cancer and diabetes
Osman, M. A., Sarkar, F. H., & Rodriguez-Boulan, E. J. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.04.005 · Cited by 30
“Underscoring the importance of signal dynamics in regulating cell and body homeostasis, are several recent studies implicating chronic administration of antidiabetic drugs, such as several types of Glucagon-like peptide-1 (GLP-1) receptor agonists, in promoting several types of cancer in human and in animal models thr…”
BackgroundThyroid safety in patients treated with liraglutide
Gallo, M. (2013) · Journal of Endocrinological Investigation · doi:10.1007/bf03346749 · Cited by 27
“GLP-1R agonists effects were not found to be mediated by MAPKinase pathway phosphorylation and by activating mutations in the RET proto-oncogene, at least on rodent Ccells (32).”
BackgroundAntihyperglycaemic therapies and cancer risk
Lutz, S. Z., Staiger, H., Fritsche, A., & Häring, H. (2014) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114549553 · Cited by 30
Pleiotropic effects of anti-diabetic drugs: A comprehensive review
Nath, M., Bhattacharjee, K., & Choudhury, Y. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173349 · Cited by 34
A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes
Montanya, E. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.692777 · Cited by 27
“Taken together, the data indicate that C-cell hyperplasia is a rodent phenomenon [85].”
BackgroundGut hormones and bone homeostasis: potential therapeutic implications
Bouvard, B., & Mabilleau, G. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01000-z · Cited by 29
“This discovery is notable because in rodents, GLP1 was previously believed to exert its anti-resorptive activity by stimulating calcitonin release from rodent thyroid C cells 91 .”
Epidemiology of Obesity and Pharmacologic Treatment Options
Shettar, V., Patel, S., & Kidambi, S. (2017) · Nutrition in Clinical Practice · doi:10.1177/0884533617713189 · Cited by 26
“Contraindications to the use of GLP-1 agonists include a personal or family history of multiple endocrine neoplasia 2 or medullary thyroid cancer, because it has been shown to increase thyroid C-cell tumors in rats.(170,171)”
BackgroundThe double trouble of metabolic diseases: the diabetes–cancer link
Tudzarova, S., & Osman, M. A. (2015) · Molecular Biology of the Cell · doi:10.1091/mbc.e14-11-1550 · Cited by 26
“This controversy has also sparked a flurry of investigations into the contexts of pancreatic cancer (Butler, 2014a; Wada and Yagihashi, 2014) and thyroid cancer (Bjerre Knudsen et al., 2010; Madsen et al., 2012; Boess et al., 2013; Waser et al., 2014), with various results.”
BackgroundSong, Y., Zhou, M., Cao, Y., Qi, J., Geng, J., & Liu, X. (2017) · Oncology Letters · doi:10.3892/ol.2017.5752 · Cited by 23
“Although previous studies have indicated that there is little or no GLP-1R expression in human thyroid C-cells (2,3), controversy remains regarding the safety of GLP-1 analogues used as anti-diabetic drugs or combined with the use of other drugs, such as proton-pump inhibitors (PPIs).”
BackgroundWebster, J. D., Santagostino, S. F., & Foreman, O. (2019) · Cell and Tissue Research · doi:10.1007/s00441-019-03101-y · Cited by 25
“GLP-1 receptors are expressed in rodent C-cells and all the effects caused by GLP-1 receptor agonists were blocked in Glp-1 receptor knockout mice (Madsen et al. 2012), thus supporting the hypothesis that the effects of GLP-1 receptor agonists on thyroid C cells are on-target.”
BackgroundGLP-1 receptor agonism: a transformative approach for managing type-2 diabetes and obesity
Alharbi, A. (2025) · Saudi Pharmaceutical Journal · doi:10.1007/s44446-025-00038-y · Cited by 34
“The primary cause for alarm is thyroid C-cell hyperplasia, which has been the subject of FDA boxed warnings since a research conducted on rats showing dose-dependent C-cell tumors (Madsen et al. 2012).”
Caparrotta, T. M., Templeton, J. B., Clay, T. A., Wild, S. H., Reynolds, R. M., Webb, D. J., & Colhoun, H. M. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01021-1 · Cited by 28
Tirzepatide—Friend or Foe in Diabetic Cancer Patients?
Samuel, S. M., Varghese, E., Kubatka, P., & Büsselberg, D. (2022) · Biomolecules · doi:10.3390/biom12111580 · Cited by 24
“However, in rodents and humans, the expression of GLP-1R and GIPR was significantly higher in MTCs compared to normal thyroid tissue across the same species [82,84].”
BackgroundUmpierrez, G. E., Bailey, T. S., Carcia, D., Shaefer, C. F., Shubrook, J. H., & SKOLNIK, N. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12576 · Cited by 25
Nyborg, N. C. B., Kirk, R. K., de Boer, A. S., Andersen, D. W., Bugge, A. K., Wulff, B. S., Thorup, I., & Clausen, T. R. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2020.115035 · Cited by 21
Self-citationQuagliariello, V., Canale, M. L., Bisceglia, I., Iovine, M., Giordano, V., Giacobbe, I., Scherillo, M., Gabrielli, D., Maurea, C., Barbato, M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011299 · Cited by 23
“Moreover, recent preclinical studies in rodents showed an increased incidence of medullary thyroid carcinoma after therapy with GLP-1 RA [113], but no data in humans are actually available.”
Kupnicka, P., Król, M., Żychowska, J., Łagowski, R., Prajwos, E., Surówka, A., & Chlubek, D. (2024) · Pharmaceuticals · doi:10.3390/ph17111470 · Cited by 26
Gigoux, V., & Fourmy, D. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00050 · Cited by 22
Incretin-based therapy for the treatment of bone fragility in diabetes mellitus
Mabilleau, G., Gobron, B., Bouvard, B., & Chappard, D. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.008 · Cited by 19
Long-term cancer risk in users of GLP-1 agonists in Denmark: a nationwide emulated trial
Gamborg, M., Grand, M. K., Grell, K., Rosthøj, S., Pedersen‐Bjergaard, U., Torp-Pedersen, C. T., & Mørch, L. S. (2025) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2025.101346 · Cited by 32
“…of GLP-1RAs on cancer development remain incompletely understood, 33 the assumption that GLP-1RAs may act as cancer promoters rather than initiators is grounded in: pre-clinical 34 and rodent studies 6,35 suggesting that GLP-1RAs may promote certain cancers via GLP-1 receptor-mediated mechanisms.”
Safety of injectable semaglutide for type 2 diabetes
Peter, R., & Bain, S. C. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1772230 · Cited by 17
Effects of anti-diabetic drugs on bone metabolism
Mabilleau, G., Chappard, D., Flatt, P. R., & Irwin, N. (2015) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2015.1077697 · Cited by 17
“Activation of GLP-1r’s in these cells is responsible for a rise in calcitonin secretion which exerts anabolic effects on bone [66].”
BackgroundInterplay between bone and incretin hormones: A review
Mabilleau, G. (2016) · Morphologie · doi:10.1016/j.morpho.2016.06.004 · Cited by 18
Forst, T. M., Block, C. E. M. D., Prato, S. D., Frías, J. P., Lautenbach, A., Ludvik, B. H., Marinez, M., Mathieu, C., Müller, T. D., & Schnell, O. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16247 · Cited by 15
“185,186 In humans, the risk of thyroid disease during incretin treatment remains controversial.”
Cao, Y., & Liu, X.-M. (2014) · Endocrine · doi:10.1007/s12020-014-0354-3 · Cited by 14
Medullary Thyroid Carcinoma Surveillance Study: A Case-Series Registry
Hale, P. M., Ali, A. K., Buse, J., McCullen, M. K., Ross, D., Sabol, M., Tuttle, R. M., & Stemhagen, A. (2020) · Thyroid · doi:10.1089/thy.2019.0591 · Cited by 9
“Studies in rodents, but not in monkeys, with clinically relevant doses of GLP-1 RAs, showed a dose-related and treatment-duration-dependent increase in the incidence of C-cell hyperplasia and C-cell tumors (adenomas and carcinomas) (2,3).”
ResultAbdul-Maksoud, R. S., Elsayed, W. S. H., Rashad, N. M., Elsayed, R. S., Elshorbagy, S., & Hamed, M. G. (2022) · Gene · doi:10.1016/j.gene.2022.146597 · Cited by 13
Current Weight Loss Medications: What Plastic Surgeons Should Know
Wirth, P. J., Shaffrey, E. C., Bay, C. C., & Rao, V. K. (2023) · Aesthetic Surgery Journal · doi:10.1093/asj/sjad304 · Cited by 13
Li, J., Xie, J., Han, Y., Zhang, W., Wang, Y., & Jiang, Z. (2024) · Endocrine Journal · doi:10.1507/endocrj.ej24-0286 · Cited by 19
“In humans, GLP-1 receptor expression in C-cells of the normal thyroid is significantly lower or absent than GLP-1 receptor expression in rodents [30, 31], so animal experiments are not representative of humans.”
Lixisenatide as add-on therapy to basal insulin
Evans, M., Butler, E. L., & Brown, D. X. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s45108 · Cited by 17
“61 This link has yet to be established in humans and may be a genotype-specific reaction in rodents.”
Antidiabetic therapy in post kidney transplantation diabetes mellitus
Werzowa, J. M., Säemann, M. D., Haidinger, M., Krebs, M., & Hecking, M. (2015) · Transplantation Reviews · doi:10.1016/j.trre.2015.01.001 · Cited by 14
“sufficient long-term data on these complications are not available, yet, especially not for patients under immunosuppressive therapy [72,73].”
BackgroundIncretin-Based Therapies and Cancer: What’s New?
Medenica, S., Bogdanović, J. M., Vekić, J., Vojinović, T., Babić, I., Bogdanovic, L. M., Maggio, V., El‐Tanani, M., & Rizzo, M. (2025) · Medicina · doi:10.3390/medicina61040678 · Cited by 13
“The implementation of GLP1-RA leads to the activation of GLP-1R in thyroid C cells, the promotion of their hyperplasia, and an increase in calcitonin synthesis, which increases the risk of the development of medullary thyroid cancer [47–49].”
Makunts, T., Joulfayan, H., & Abagyan, R. A. (2024) · JMIRx Med · doi:10.2196/55976 · Cited by 14
Can we win the war on obesity with pharmacotherapy?
Gotthardt, J. D., & Bello, N. T. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2016.1232164 · Cited by 12
“[66], but this mechanism of action in humans is not clear [67].”
Backgroundvan den Brink, W., Emerenciana, A., Bellanti, F., Pasqua, O. E. D., & van der Laan, J. W. (2017) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2017.02.010 · Cited by 16
Exenatide Treatment Reduces Thyroid Gland Volume, but Has No Effect on the Size Of Thyroid Nodules
Köseoğlu, D., Başer, Ö. Ö., Berker, D. S., & Cekic, S. G. (2020) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2020.275 · Cited by 20
“Animal studies have shown that exenatide increases serum calcitonin levels, and also the risk for C-cell adenomas (5-8).”
BackgroundIncretins and bone: friend or foe?
Mabilleau, G. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.03.007 · Cited by 14
“Now, we know that in rodents, but not in non-human primate or humans, GLP-1r is expressed in C-cells of the thyroid gland, and responsible for a rise in calcitonin secretion [65].”
BackgroundWu, H., Lu, Z., Chen, R., Cai, Q., Wang, M., Zhang, L., & Zhu, Z. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1098032 · Cited by 15
“Several studies have found that GLP-1 receptor agonists may cause thyroid C-cell adenomas and C-cell carcinomas in rodents (26, 27), and thus GLP-1 receptor agonists are contraindicated in those with a history of medullary thyroid cancer.”
BackgroundGLP-1 receptor agonist as treatment for cancer as well as diabetes: beyond blood glucose control
Nomiyama, T., & Yanase, T. (2016) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2016.1191349 · Cited by 14
“performed an in vivo examination using GLP-1 receptor deficient mice [33].”
MethodLiraglutide Therapy in a Prediabetic State: Rethinking the Evidence
Papaetis, G. S. (2019) · Current Diabetes Reviews · doi:10.2174/1573399816666191230113446 · Cited by 11
Wawrzak-Pienkowska, K., Pienkowski, T., Golonko, A., Krupa, A., Warpechowski, M., Płoński, A. F., Mojsak, P., Daniluk, J., Dâbrowski, A., & Kurek, K. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178290 · Cited by 12
Dadu, R., Bagheri‐Yarmand, R., Ringel, M. D., Grubbs, E. G., Zafereo, M., Cote, G. J., Gagel, R. F., Robinson, B. G., Shaw, K. R. M., & Hu, M. I.-N. (2020) · Endocrine Related Cancer · doi:10.1530/erc-20-0110 · Cited by 11
GLP-1 Receptor Agonists and Noncardiometabolic Outcomes: An Umbrella Review of Meta-Analyses
Yang, K., Liu, C., Guo, Q., & Li, Y. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.4722 · Cited by 15
Update on: effects of anti-diabetic drugs on bone metabolism
Mabilleau, G., & Bouvard, B. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1831911 · Cited by 9
A systematic review of the safety of incretin-based therapies in type 2 diabetes
Evans, M., Bain, S. C., & Vora, J. P. (2016) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2015.1057502 · Cited by 8
“Because some preclinical studies suggest a relationship between GLP-1 RA treatment and thyroid C-cell proliferation [65,66], this area continues to be monitored closely in ongoing and future clinical trials using”
BackgroundZheng, M., Zhao, J., Wang, Y., Cui, Z., Qiao, Z., Wu, H., Shi, C., & Wang, X. (2025) · Medicine · doi:10.1097/md.0000000000043239 · Cited by 9
Updates on Anti-Obesity Medications in Children and Adolescents
Salama, M., Hassan, D., & Kumar, S. (2025) · Children · doi:10.3390/children12101390 · Cited by 10
“Additionally, stimulation of calcitonin release has been reported in rodents exposed to liraglutide and exenatide [65].”
Vahle, J. L., Dybowski, J., Graziano, M. J., Hisada, S., Lebron, J., Nolte, T., Steigerwalt, R. W., Tsubota, K., & Sistare, F. D. (2024) · Frontiers in Toxicology · doi:10.3389/ftox.2024.1377990 · Cited by 7
Metadata
- Authors
- Madsen, L. W., Knauf, J. A., Gotfredsen, C., Pilling, A., Sjögren, I., Andersen, S., Andersen, L., Sietske de Boer, A., Manova, K., Barlas, A., Vundavalli, S., Nyborg, N. C. B., Bjerre Knudsen, L., Moelck, A. M., & Fagin, J. A.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Memorial Sloan Kettering Cancer Center (US)
- Huntingdon Life Sciences (A.P.), Eye, Suffolk, IP23 7PX, United Kingdom
- Novo Nordisk A/S (L.W.M., C.G., I.S., S.A., L.A., A.S.d.B., N.C.B.N., L.B.K., A.M.M.), Novo Allé, DK-2880, Bagsvaerd, Denmark
- Memorial Sloan-Kettering Cancer Center (J.A.K., K.M., A.B., S.V., J.A.F.), New York, New York 10065
- Corresponding author
- Madsen, Lars Wichmann
- Fagin, James A.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2012-03-01
- Volume
- 153
- Issue
- 3
- Pages
- 1538-1547
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- PMC
- PMC3281535
- OpenAlex
- W2166969890
- Cited by
- 161
- References
- 29
- Citations by year
- 2026: 27 · 2025: 24 · 2024: 15 · 2023: 5 · 2022: 4 · 2021: 2 · 2020: 12 · 2019: 8 · 2018: 6 · 2017: 7 · 2016: 8 · 2015: 11 · 2014: 11 · 2013: 15 · 2012: 6
- FWCI
- 11.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Endocrinology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA-72597, R01CA072597)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Keywords
- GLP-1 receptor agonists, liraglutide, exenatide, RET proto-oncogene, calcitonin, mTOR signaling, type 2 diabetes
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Animals, Calcitonin, Female, Immunohistochemistry, Ligands, Male, Models, Genetic, Phosphoproteins, Thyroid Gland, Time Factors, Signal Transduction, Receptors, Glucagon, Mice, Knockout, Proto-Oncogene Proteins c-ret, Mice, Glucagon-Like Peptide 1, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.